Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Debt: 2010-2024

Historic Total Debt for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $2.5 million.

  • China Pharma Holdings' Total Debt fell 20.78% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year decrease of 1.16%. This contributed to the annual value of $2.5 million for FY2024, which is 0.38% down from last year.
  • Latest data reveals that China Pharma Holdings reported Total Debt of $2.5 million as of FY2024, which was down 0.38% from $2.5 million recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Total Debt registered a high of $4.3 million during FY2021, and its lowest value of $2.4 million during FY2022.
  • Its 3-year average for Total Debt is $2.5 million, with a median of $2.5 million in 2024.
  • In the last 5 years, China Pharma Holdings' Total Debt soared by 47.11% in 2021 and then slumped by 43.61% in 2022.
  • Over the past 5 years, China Pharma Holdings' Total Debt (Yearly) stood at $2.9 million in 2020, then skyrocketed by 47.11% to $4.3 million in 2021, then crashed by 43.61% to $2.4 million in 2022, then rose by 4.29% to $2.5 million in 2023, then fell by 0.38% to $2.5 million in 2024.